Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | HTR1E | P28566 | 1/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2267443 | 0.69 | CHRNB2 (0.43) | CHRNB2ADRA1DHTR1ECHRNA3ADRA1A | |
| SCHEMBL9301475 | 0.67 | ATAD2 (0.46) | ADORA2BCYP3A4ALDH1A1CYP2C19MAPT | |
| SCHEMBL16870007 | 0.64 | CHRNB2 (0.57) | CHRNB2ADRA1DHTR1ECHRNA3ADRA1A | |
| SCHEMBL13875830 | 0.64 | CHRNB2 (0.49) | CHRNB2ADRA1DHTR1ECHRNA3ADRA1A | |
| SCHEMBL2386923 | 0.64 | MEN1 (0.69) | ALDH1A1 | |
| SCHEMBL9300537 | 0.63 | DPP4 (0.32) | KDM4E | |
| SCHEMBL3232066 | 0.63 | PDE4A (0.52) | ADORA2BALDH1A1HSD17B10KDM4E | |
| SCHEMBL10712628 | 0.62 | KDM4E (0.76) | ADORA2BCYP3A4ALDH1A1HSD17B10KDM4E | |
| SCHEMBL23679607 | 0.62 | CHRNB2 (0.54) | CHRNB2ADRA1DHTR1ECHRNA3ADRA1A | |
| SCHEMBL21895399 | 0.62 | CHRNB2 (0.54) | CHRNB2ADRA1DHTR1ECHRNA3ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034137-A1 | Compositions and Methods for Cellular Ageing, Stress Resilience, Autophagy, Inflammation and Longevity | JUVN3 HOLDINGS, LLC (US) | 2026-02-05 | — | — | US | claimed |
| US-12533327-B2 | Hexylamine salts and methods of using hexylamine | THERMOLIFE INTERNATIONAL, LLC (US) | 2026-01-27 | — | — | US | claimed |
| US-20240016764-A1 | HEXYLAMINE SALTS AND METHODS OF USING HEXYLAMINE | THERMOLIFE INTERNATIONAL, LLC | 2024-01-18 | — | — | US | claimed |
| EP-3651770-B1 | THEACRINE-BASED SUPPLEMENT AND METHOD OF USE THEREOF IN A SYNERGISTIC COMBINATION WITH CAFFEINE | ORTHO NUTRA LLC (US) | 2023-11-08 | — | — | EP | claimed |
| WO-2023064511-A9 | PARAXANTHINE-BASED BIOACTIVE COMPOSITION AND METHOD OF USE THEREOF | Ingenious Ingredients, LP (US) | 2023-06-08 | — | — | WO | claimed |
| US-20230149412-A1 | Compositions and Methods for Cellular Ageing, Stress Resilience, Autophagy, Inflammation and Longevity | JUVN3 HOLDINGS, LLC (US) | 2023-05-18 | — | — | US | claimed |
| WO-2023064511-A1 | PARAXANTHINE-BASED BIOACTIVE COMPOSITION AND METHOD OF USE THEREOF | Ingenious Ingredients, LP (US) | 2023-04-20 | — | — | WO | claimed |
| US-20230115966-A1 | PARAXANTHINE-BASED BIOACTIVE COMPOSITION AND METHOD OF USE THEREOF | PX ING, LLC | 2023-04-13 | — | — | US | claimed |
| US-20230072854-A1 | PARAXANTHINE-BASED BIOACTIVE COMPOSITION AND METHOD OF USE THEREOF | PX ING, LLC | 2023-03-09 | — | — | US | claimed |
| US-20230025435-A1 | COMPOSITIONS AND METHODS FOR INCREASING CELLULAR VITALITY AND LONGEVITY AND DECREASING MOLECULAR AGEING | JUVN3 HOLDINGS, LLC (US) | 2023-01-26 | — | — | US | claimed |
| US-11541020-B2 | Hexylamine salts and methods of using hexylamine | THERMOLIFE INTERNATIONAL, LLC (US) | 2023-01-03 | — | — | US | claimed |
| EP-4093296-A1 | PARAXANTHINE-BASED BIOACTIVE COMPOSITION AND METHOD OF USE THEREOF | Ingenious Ingredients, LP (US) | 2022-11-30 | — | — | EP | claimed |
| US-9468645-B2 | Highly soluble purine bioactive compounds and compositions thereof | ENERGY BEVERAGES LLC | 2016-10-18 | — | — | US | claimed |
| US-20150238494-A1 | HIGHLY SOLUBLE PURINE BIOACTIVE COMPOUNDS AND COMPOSITIONS THEREOF | ENERGY BEVERAGES LLC | 2015-08-27 | — | — | US | claimed |
| EP-3068240-B1 | THEACRINE-BASED SUPPLEMENT AND METHOD OF USE THEREOF | ORTHO NUTRA LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260062414-A1 | NOVEL COCRYSTALS OF METHYLXANTHINES, THEIR POLYMORPHS AND PROCESS THEREOF | FERTIS INDIA PVT LTD (IN) | 2026-03-05 | — | — | US | disclosed |
| US-20260034137-A1 | Compositions and Methods for Cellular Ageing, Stress Resilience, Autophagy, Inflammation and Longevity | JUVN3 HOLDINGS, LLC (US) | 2026-02-05 | — | — | US | disclosed |
| US-11426410-B2 | Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine | ORTHO-NUTRA, LLC (US) | 2022-08-30 | — | — | US | disclosed |
| US-9468645-B2 | Highly soluble purine bioactive compounds and compositions thereof | ENERGY BEVERAGES LLC | 2016-10-18 | — | — | US | disclosed |
| US-20150238494-A1 | HIGHLY SOLUBLE PURINE BIOACTIVE COMPOUNDS AND COMPOSITIONS THEREOF | ENERGY BEVERAGES LLC | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062414-A1 | NOVEL COCRYSTALS OF METHYLXANTHINES, THEIR POLYMORPHS AND PROCESS THEREOF | HTR3B, PDE4A, SLC6A3 | CHRNB2 300/4885ADRA1D 1772/4885HTR1E 12/4885 |
| US-20150238494-A1 | HIGHLY SOLUBLE PURINE BIOACTIVE COMPOUNDS AND COMPOSITIONS THEREOF | ADORA2A, PNP, P2RX6 | CHRNB2 3318/4885ADRA1D 1844/4885HTR1E 799/4885 |
| US-12533327-B2 | Hexylamine salts and methods of using hexylamine | SLC6A2, SLC6A3, COMT | CHRNB2 151/4885ADRA1D 115/4885HTR1E 25/4885 |
| US-20240016764-A1 | HEXYLAMINE SALTS AND METHODS OF USING HEXYLAMINE | SLC6A2, CPT1B, CHAT | CHRNB2 522/4885ADRA1D 1485/4885HTR1E 400/4885 |
| US-11541020-B2 | Hexylamine salts and methods of using hexylamine | SLC6A2, CPT1B, GYS1 | CHRNB2 485/4885ADRA1D 1460/4885HTR1E 357/4885 |
| US-20260034137-A1 | Compositions and Methods for Cellular Ageing, Stress Resilience, Autophagy, Inflammation and Longevity | TFAM, POT1, CLPX | CHRNB2 3823/4885ADRA1D 4148/4885HTR1E 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.